Hansen F, Malthe I, Krog H
Department of Oncology, Herlev University Hospital, Denmark.
Gynecol Oncol. 1990 Mar;36(3):369-70. doi: 10.1016/0090-8258(90)90144-a.
Antitumor effect and toxicity of single-drug treatment with per oral VP-16-213 (etoposide) were evaluated in a phase II trial which included 22 patients with recurrence or progression of ovarian carcinoma. Two of these patients were evaluable only for toxicity. All patients had previously been treated with a combination chemotherapy involving at least three different drugs. The median age was 59 years (range 21-76). VP-16-213 was administered orally at a daily dose of 200 mg/m2 for 4 consecutive days every third week with systematic dose escalation. Fourteen patients were treated to grade 3-4 hematologic toxicity (WHO) and 8 to grade 0-2. Eleven experienced nausea and vomiting and 4 partial alopecia. One patient achieved a CR and another a PR with a duration of 3 months and 5 + months, respectively.
在一项II期试验中评估了口服VP - 16 - 213（依托泊苷）单药治疗的抗肿瘤效果和毒性，该试验纳入了22例卵巢癌复发或进展的患者。其中2例患者仅可评估毒性。所有患者此前均接受过至少三种不同药物的联合化疗。中位年龄为59岁（范围21 - 76岁）。VP - 16 - 213口服给药，剂量为200mg/m²，每三周连续4天给药，同时进行系统的剂量递增。14例患者出现3 - 4级血液学毒性（世界卫生组织标准），8例为0 - 2级。11例出现恶心和呕吐，4例出现部分脱发。1例患者达到完全缓解，另1例部分缓解，缓解持续时间分别为3个月和5 +个月。
